The first group to relate the upregulation of HMGA2 and MPN was Guglielmelli et al.; studying the molecular profile in PMF of CD34+ cells, they observed the presence of the JAK2V617F mutation that influenced the abnormal expression of HMGA2 [125]. The gene discussed is HMGA2; the disease is myeloproliferative neoplasm.